4-Ethylbenzenecarboximidamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Ethylbenzenecarboximidamide
• 化学式: C₉H₁₂N₂
• mdl: MFCD09745474
• 分子量: 148.2
• InChiKey: FZMLKENAMKEQOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• beta-sheet mimetics and composition and methods relating thereto
  申请人：Myriad Pharmaceuticals, Inc.

  公开号：US20040014763A1

  公开（公告）日：2004-01-22

  Compounds having the following structure: 1 including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A′, B, X, Y, R 2 , R 3 , R 4 and R 5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are tryptase antagonists.

  具有以下结构的化合物：1，包括药用可接受的盐及其立体异构体，其中A、A'、B、X、Y、R2、R3、R4和R5如本文所定义。这些化合物在广泛的应用范围内具有实用性，包括用作诊断和治疗剂。特别是，本发明的化合物和含有这些化合物的药物组合物是色胺酸蛋白酶抑制剂。
• Novel Urokinase Inhibitors
  申请人：Augustyns Koen

  公开号：US20080312191A1

  公开（公告）日：2008-12-18

  The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to the use of said uPA inhibitor compounds as a medicament and the use of said uPA inhibitor compounds for the preparation of a medicament for the treatment of conditions chosen from the group comprising cancer, tumour growth, tumour invasion, tumour metastasis, diabetic retinopathy, hemorrhagic atherosclerosis and inflammatory conditions, such as rheumatoid arthritis and psoriasis.

  本发明涉及具有抑制尿激酶纤溶酶原活化物（uPA）活性的新化合物；制备所述uPA抑制剂化合物的方法；包括所述uPA抑制剂化合物的药物组合物；将所述uPA抑制剂化合物用作药物的用途以及将所述uPA抑制剂化合物用于制备用于治疗癌症、肿瘤生长、肿瘤侵袭、肿瘤转移、糖尿病视网膜病变、出血性动脉粥样硬化和类风湿性关节炎和银屑病等条件的药物的用途。
• TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE
  申请人：Steinmetzer Torsten

  公开号：US20100022781A1

  公开（公告）日：2010-01-28

  The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

  该发明涉及一般式（I）的胰蛋白酶样丝氨酸蛋白酶抑制剂，除了抑制纤溶酶外，还抑制血浆激肽原，以及它们的制备和用作药物，优选用于治疗失血，特别是在高纤溶状态、器官移植或心脏手术干预，特别是心肺转流手术中，或作为纤维蛋白粘合剂的组分。
• SELECTIVE TMPRSS2 INHIBITORS AND MEDICAL USE THEREOF
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3925667A1

  公开（公告）日：2021-12-22

  The invention relates to the compound of general formula (I) as novel inhibitors of TMPRSS2 and their use for the prophylaxis and treatment of influenza virus infection or coronavirus infection, in particular, SARS-CoV2 (COVID-19) infection.

  该发明涉及一种一般式（I）的化合物，作为TMPRSS2的新型抑制剂，用于预防和治疗流感病毒感染或冠状病毒感染，特别是SARS-CoV2（COVID-19）感染。
• Organic Electroluminescent Materials and Devices
  申请人：Universal Display Corporation

  公开号：US20170170414A1

  公开（公告）日：2017-06-15

  This invention discloses iridium complexes containing hexadenate ligands. The multidenate iridium complexes showed desired properties in term of EQE, LT, CIE, etc.

  本发明揭示了含有六酰胺配体的铱配合物。多齿配位的铱配合物在EQE、LT、CIE等方面表现出期望的性质。